Latest Breaking News On - அகாடியா மருந்துகள் - Page 5 : comparemela.com

Share this article Share this article NEW YORK, June 10, 2021 /PRNewswire/  Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ( Acadia or the Company )(NASDAQ: ACAD) and certain of its officers.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyUnited states district courtSecurities exchangeDrug administrationPomerantz firmAcadia pharmaceuticals incAcadia pharmaceuticalsSouthern districtSecurities exchange actClass periodLead plaintiff